| 16750840 |
Molina-Molina JM, Hillenweck A, Jouanin I, Zalko D, Cravedi JP, Fernandez MF, Pillon A, Nicolas JC, Olea N, Balaguer P: Steroid receptor profiling of vinclozolin and its primary metabolites. . Toxicol Appl Pharmacol. 2006 Oct 1;216(1):44-54. Epub 2006 Jun 5.
Vinclozolin, M1 and M2 were agonists for both ERs with a lower affinity for ERbeta. |
112(1,2,2,2) |
Details |
| 17980475 |
Loutchanwoot P, Wuttke W, Jarry H: Effects of a 5-day treatment with vinclozolin on the hypothalamo-pituitary-gonadal axis in male rats. Toxicology. 2008 Jan 14;243(1-2):105-15. Epub 2007 Sep 29.
Our results revealed that (i) VZ decreases epididymis weights, increases serum levels of LH and T, and decreases serum TSH and total T (4) levels; (ii) VZ affects the hypothalamic expression of both estrogen receptor (ERs) subtypes, ERalpha and ERbeta; (iii) in the extrahypothalamic brain areas, VZ alters expression of ERs and androgen receptor (AR); (iv) in the pituitary, VZ up-regulates expression of the GnRH receptor, LHbeta, alpha-subunit, and TERP-1/-2; (v) in the ventral prostate, VZ increases and decreases levels of AR and ERbeta mRNA, respectively; (vi) in the seminal vesicles, VZ increases levels of AR and ERalpha mRNA expressions; (vii) in the epididymis, VZ up-regulates AR and ERbeta mRNA expression. |
1(0,0,0,1) |
Details |